Complete drug study data should be uploaded on EU's public database

02/7/2013 | Public Service Europe

Drugmakers and researchers should publish comprehensive findings from clinical studies on the public European Union database, writes the Labour Party's Glenis Willmott, a member of the European Parliament. Summaries may be influenced by bias and could inflate drugs' value, Willmott writes. Financial penalties should be used to enforce transparency, Willmott writes.

View Full Article in:

Public Service Europe

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide